


PRODUCT INFORMATION



Exemestane

Item No. 15008

CAS Registry No.: 107868-30-4
Formal Name: 6-methylene-androsta-1,4-diene-3,17-dione
Synonyms: Aromasin™, FCE 24304
MF: C₂₀H₂₄O₂
FW: 296.4
Purity: ≥95%
UV/Vis.: λ_{max}: 246 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Exemestane is supplied as a crystalline solid. A stock solution may be made by dissolving the exemestane in the solvent of choice. Exemestane is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of exemestane in ethanol is approximately 20 mg/ml and approximately 30 mg/ml in DMSO and DMF.

Exemestane is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, exemestane should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Exemestane has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Exemestane is a third generation, irreversible steroidal aromatase inhibitor ($K_i = 10.2$ nM; $K_{inact} = 26$ nM) that induces aromatase degradation leading to a decrease in estrogen levels in plasma.^{1,2} As an androgen analog, exemestane exhibits androgenic effects and has been shown to decrease total and HDL cholesterol, apo A₁, and total triglyceride levels.³ Marketed under the trade name Aromasin™, exemestane has been used to treat estrogen receptor-positive breast cancers in post-menopausal women.¹

References

1. Wang, X. and Chen, S. Aromatase destabilizer: Novel action of exemestane, a food and drug administration-approved aromatase inhibitor. *Cancer Res.* **66(21)**, 10281-10286 (2006).
2. Santen, R.J. and Harvey, H.A. Use of aromatase inhibitors in breast carcinoma. *Endocr. Relat. Cancer* **6(1)**, 75-92 (1999).
3. Buzdar, A.U., Robertson, J.F.R., Eiermann, W., et al. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. *Cancer* **95(9)**, 2006-2016 (2002).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/05/2018

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM